Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ClearPoint NeuroCLPT +1.48%63 3-1 Month Momentum % is 42.16% as of Aug. 12, 2026. GuruFocus rates CLPT with a GF Score™ of 63/100 and a GF Value™ of $14.14 (Fairly Valued). The stock has 8 warning signs investors should review. Among 849 Medical Devices & Instruments companies, ClearPoint Neuro ranks better than 96.7% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-12), ClearPoint Neuro's 3-1 Month Momentum % is 42.16%.
The industry rank for ClearPoint Neuro's 3-1 Month Momentum % or its related term are showing as below:
CLPT's 3-1 Month Momentum % is ranked better than 96.7% of 849
companies
in the Medical Devices & Instruments industry
Industry Median: -7.11
vs CLPT: 42.16
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
ClearPoint Neuro 3-1 Month Momentum % Related Terms
CLPT vs SI, PACB, DCTH: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, ClearPoint Neuro's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ClearPoint Neuro 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ClearPoint Neuro's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where ClearPoint Neuro's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ClearPoint Neuro (CLPT) has a 3-1 Month Momentum % of 42.16% as of Aug. 12, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on ClearPoint Neuro and its competitors. According to the industry distribution chart, ClearPoint Neuro ranks #28 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 3.3%.
Is ClearPoint Neuro's 3-1 Month Momentum % too high?
ClearPoint Neuro's current 3-1 Month Momentum % is 42.16%. Based on the distribution chart, ClearPoint Neuro ranks #28 out of 849 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ClearPoint Neuro has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ClearPoint Neuro's 3-1 Month Momentum % compare to SI and PACB?
According to the Medical Devices & Instruments industry distribution chart, ClearPoint Neuro ranks #28 out of 849 companies for 3-1 Month Momentum %. This places ClearPoint Neuro in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on ClearPoint Neuro and its competitors. ClearPoint Neuro's current 3-1 Month Momentum % is 42.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ClearPoint Neuro stock overvalued right now?
Based on GuruFocus' analysis, ClearPoint Neuro (CLPT) is currently considered Fairly Valued. The stock's GF Value™ is $14.14, compared to a current price of $15.11 — trading 6.9% above its estimated fair value. The current 3-1 Month Momentum % is 42.16%. ClearPoint Neuro's overall GF Score™ is 63/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For ClearPoint Neuro (CLPT), the current 3-1 Month Momentum % is 42.16% as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ClearPoint Neuro (CLPT) Overvalued in 2026?
Based on GuruFocus' analysis, ClearPoint Neuro stock appears to be overvalued.
The current stock price of $15.11 is trading 6.9% above its estimated GF Value™ of $14.14.
GuruFocus considers ClearPoint Neuro to be Fairly Valued.
Key valuation signals for CLPT:
3-1 Month Momentum %: 42.16%
GF Value™: $14.14 vs. price of $15.11 (6.9% above fair value)
No single metric tells the full story. See the CLPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
63GF Score
Get the complete analysis for CLPT
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPT has been successfully added to your 
